Symbiotec Pharmalab IPO saw solid demand from investors as the issue ended up getting oversubscribed 71.26 times overall against the 1.31 crore shares available for subscription by the final day of subscription, showed NSE data.
The IPO has been subscribed 5.31 times overall against the 1.31 crore shares on offer. The retail portion has been subscribed 5.05 times, against 65.44 lakh shares reserved for retail investors.